Innovative Risk Assessment:

            When regulatory agencies calculate risk characterizations, they usually assume a linear extrapolation from the high doses in an animal study to the projected low-dose human exposure. This approach sometimes leads to results that are counterintuitive and don't match the underlying data. Sielken & Associates has developed software to apply more appropriate dose-response models and has developed alternative risk assessment techniques to more accurately characterize human risks based on animal or human epidemiological studies.

            The new approaches applied by Sielken & Associates provide more and better scientific information on quantitative risk.

            Sielken & Associates use probabilistic techniques that can frequently avoid the compounding effect of multiple worst-case conservative assumptions and provide alternative, more realistic risk characterizations.

            Sielken & Associates use emerging risk characterization procedures that facilitate risk-benefit analyses and promote greater utilization of the tools of risk management.